Similar articles

• [Novel molecular approaches in the therapy of advanced colorectal carcinoma].

  Vanhoefer U. Vanhoefer U. Onkologie. 2003 Dec;26 Suppl 7:70-4. doi: 10.1159/000076178. Onkologie. 2003. PMID: 14716146 Review. German.
• Integration of novel agents in the treatment of colorectal cancer.

  Iqbal S, Lenz HJ. Iqbal S, et al. Cancer Chemother Pharmacol. 2004 Sep;54 Suppl 1:S32-9. doi: 10.1007/s00280-004-0884-0. Cancer Chemother Pharmacol. 2004. PMID: 15309512 Review.
• Emerging therapies for metastatic colorectal cancer: focus on EGFR and VEGF inhibition.

  Venook AP. Venook AP. J Natl Compr Canc Netw. 2004 Sep;2 Suppl 2:S74-84. J Natl Compr Canc Netw. 2004. PMID: 19780248 Review.
• Re: Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer.

  Normanno N, Tejpar S, Ciardiello F. Normanno N, et al. J Natl Cancer Inst. 2010 Apr 21;102(8):573; author reply 573-5. doi: 10.1093/jnci/djq064. Epub 2010 Mar 19. J Natl Cancer Inst. 2010. PMID: 20305131 No abstract available.
• Where to position monoclonal antibodies in first-line treatment of advanced colorectal cancer.

  Jackson C, Cunningham D. Jackson C, et al. Eur J Cancer. 2008 Mar;44(5):652-62. doi: 10.1016/j.ejca.2008.01.021. Epub 2008 Mar 3. Eur J Cancer. 2008. PMID: 18313913 Review.